

ANGLE – transforming cancer care with a liquid biopsy from a simple blood test

www.angleplc.com

ANGLE (AIM:AGL) is a world-leading liquid biopsy company that has developed pioneering products and services in cancer diagnostics using a simple blood test.

ANGLE's patent protected platforms include the Parsortix system, a marker independent circulating tumour cell (CTC) technology that captures and harvests cancer cells shed by the tumour into the blood, and HyCEAD a downstream analysis system for highly sensitive analysis of DNA, RNA and proteins.

ANGLE believes that analysis of CTCs allows the complete picture of the cancer to be understood as it captures intact living cells that can provide DNA, RNA or protein information.

It is estimated that as many as one in two people will get cancer during their lifetime (CRUK), with cancer responsible for an estimated 10 million deaths globally in 2020. The number of cancer cases is growing rapidly with a 50% increase in cases expected over the next two decades.

ANGLE is building a differentiated position as a



global leader in the emerging liquid biopsy market offering a unique product-based solution in addition to the traditional laboratory service-based approach, accelerating the widespread adoption of the Parsortix system. Frost & Sullivan and Cowen have estimated that the liquid biopsy market will be worth \$100 billion and up to \$130 billion per annum respectively in the US alone.

COVID-19 AND CANCER – THE URGENT NEED FOR LIQUID BIOPSY

Covid-19 has caused an unprecedented crisis in cancer diagnosis and care with implications for years to come. Ending delays and addressing backlogs, particularly cancer diagnostic tests and treatment, is an urgent priority for healthcare systems.

The standard test for identifying and understanding

cancer is to undertake a solid tissue biopsy. However, tissue biopsy is invasive, costly, time-consuming, and potentially harmful. These factors make solid tissue biopsy unsuitable for repeat, longitudinal monitoring required to ensure the right drug for the right patient at the right time.

The information provided by liquid biopsy could help clinicians diagnose, treat and monitor cancer more effectively. Liquid biopsy is non-invasive, repeatable and can be undertaken in the community to provide patients with a rapid diagnosis and timely treatment with targeted therapies. Liquid biopsy may also help to safely monitor cancer patients in remission to provide early warning of recurrence.

The adverse impact of Covid-19 on cancer diagnosis and care has shown that it is essential to have a diagnostic tool which is quick, easy and alleviates the burden of conducting hospital-based surgical tissue biopsies or radiological imaging. ANGLE believes its Parsortix system can help to meet that urgent need.

ACCELERATING WIDESPREAD ADOPTION OF THE PARSORTIX SYSTEM

ANGLE made significant progress towards achieving widespread adoption of the Parsortix system in 2020 and momentum has gathered pace in 2021. Achievements include:

Regulatory submission to the FDA for clearance of the Parsortix system in metastatic breast cancer was made in September 2020. This submission included results from over 15,000 samples and 400 reports. The submission cleared Administrative Review



and is now under Substantive Review with approval anticipated in H2, 2021. FDA clearance would be the first of its kind for the intended use and position the Parsortix system as the gold standard in CTC harvesting.

Clinical Services Laboratories were launched in the US and UK. The laboratories allow ANGLE to accelerate the commercial deployment of the Parsortix system by offering services to pharmaceutical and biotech customers for use in cancer drug clinical trials and through the provision of Laboratory Developed Tests (LDTs) for patient care.

ANGLE secured its first large-scale pharma services contract valued at up to \$1.2 million over 18 months with potential for further contracts from this customer. The customer, a pharma company with numerous cancer drugs under development and forecast revenues exceeding US\$1 billion per annum, has selected ANGLE to undertake longitudinal monitoring (i.e. before, during and after drug intervention) of patients in a prostate cancer Phase III global clinical trial. The same customer has engaged ANGLE in two smaller Phase I studies.

ANGLE's Ovarian Clinical

Verification study, being run out of a leading US cancer centre, has completed patient enrolment. Assuming positive results this will allow for the launch of its first LDT for detection of ovarian cancer for pelvic mass triage towards the end of CY 2021.

BUILDING ON A LEADING POSITION IN THE LIQUID BIOPSY MARKET

Led by an experienced management team, ANGLE has a track record of delivering on its strategic objectives and is well positioned to capitalise on its strong position as it moves from intensive product development into commercialisation. In 2021, ANGLE will continue to deliver on its strategic aims to position itself as a leader in the liquid biopsy market which will revolutionise cancer diagnosis and care for millions of patients worldwide, an unmet need which the Covid-19 pandemic has intensified.

